sugars in diabetes comprising CON-1, CON-2, or bioactive fragments retaining AGS inhibitory activity in a dose encapsulated in an enteric coating;

(8) an injectable composition for inhibiting proliferation of HIV-1 comprising a bioactive fragment of CON-1 or CON-2 having AGS inhibitory activity, dissolved in diluent;

(9) a synthetic glycosylated peptide having the AGS inhibitory activity of CON-1 protein comprising a tetrapeptide of primary structure of formula (I):

Gly-Gly-Asn(acetylglucosamine)-Lys (I);

(10) a carrier glycosylated tetrapeptide comprising a tetrapeptide of structure (I), and a carrier, and

(11) a synthetic glycosylated pyridoxylated peptide having an enhanced AGS inhibitory activity compared to the inhibitory activity of the unmodified peptide comprising a tetrapeptide of primary structure of formula (II):

Gly-Gly-Asn(acetyl-glycosamine)-pyridoxyl-Lys (II).

USE - The salivary glycoproteins CON-1 and CON-2 and derivatives, have AGS inhibitory activity and can be used to treat patients with diabetes or patients infected with retroviruses such as HIV.

Dwg.0/0

Derwent Class: B04; D16
International Patent Class (Main): C07H-021/04; C08H-001/00
International Patent Class (Additional): A61K-038/00; C07K-001/00; C07K-001/16; C07K-001/30; C07K-005/00; C07K-014/00

011728306
WPI Acc No: 1998-145216/199813

Delayed and sustained release compositions for absorption in colon - comprise active ingredient e.g. diamorphine or cocaine in e.g. tablet form with enteric coating

Patent Assignee: EVANS B K (EVAN-I); RHODES J (RHOD-I)
Inventor: EVANS B K; RHODES J
Number of Countries: 078 Number of Patents: 002
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9802148	A2	19980122	WO 97GB1935	A	19970716	199813	B
AU 9735530	A	19980209	AU 9735530	A	19970716	199823	

Priority Applications (No Type Date): GB 9614902 A 19960716
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9802148	A2	E	27	A61K-031/00	

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9735530	A	A61K-031/00	Based on patent WO 9802148

Abstract (Basic): WO 9802148 A

Rectally administrable and post-gastric delayed release oral composition comprises at least one active ingredient (I) selected from diamorphine, morphine, cocaine, theophylline, aminophylline, phenytoin, carbamazepine, phenobarbitone, cyclosporin, diazepam, nitrazepam,

temazepam and/or their salts and a carrier. Also claimed are: (i) a delayed and sustained release capsule for selectively delivering (I) to the colon, the capsule comprising (I) or their derivatives or metabolites in the form of enterically coated granules of (I) adapted to predominantly release (I) in the colon, the capsule including an outer enteric coating which dissolves in the terminal ileum to release the granules for absorption in the colon; (ii) a delayed and sustained release tablet, capsule or granule for oral administration comprising a complex of (I) or its derivatives or metabolites and a carbomer; (iii) a delayed and sustained release oral capsule comprising (I) or a salt incorporated into a heat meltable polyglyceride fatty acid excipient and encapsulated into the capsule, the capsule having an outer enteric coating which dissolves in the terminal ileum for absorption of (I) predominantly in the colon; and (iv) a complex of diamorphine polyacrylate and cocaine polyacrylate.

USE - The composition provides sustained release of active agent for absorption from the colon.

ADVANTAGE - The composition provides strict control and limits peak plasma levels of drugs, reducing the possibilities of addiction and/or toxic side effects. Oral or rectal administration is much more convenient than intravenous or subcutaneous fusion of these drugs which is both uncomfortable and often requires hospitalisation.

Dwg.0/2

Derwent Class: A96; B02; B07
International Patent Class (Main): A61K-031/00